London Daily

Focus on the big picture.
Saturday, Aug 02, 2025

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill
Pfizer has made nearly $26bn (£21bn) in revenues in the first three months of the year, the bulk from its Covid-19 vaccine and new pill to treat the virus, prompting fresh accusations of pandemic profiteering.

Covid vaccines have saved many lives around the world and relieved the pressure on health systems, but Pfizer has faced criticism over its vaccine pricing and its refusal to waive patent protection to enable others to make the jab.

Last week 35 campaigners from Global Justice Now, Act-Up London, Just Treatment and Stop Aids protested against what they call pandemic profiteering, and delivered wheelbarrows full of fake money to Pfizer’s UK headquarters in Surrey on the day of the company’s annual shareholder meeting.

The New York-based firm posted total sales of $25.7bn in the first quarter, up 77% from a year earlier. Of this, $13.2bn came from the Comirnaty jab it developed with Germany’s BioNTech, driven by global uptake including jabs for children over the age of five, and booster doses. Pfizer and BioNTech are also seeking US approval for the vaccine’s use in children from six months to four years old.

A further $1.5bn came from Paxlovid, a Covid pill for people who are at high risk of severe disease, including hospitalisation or death. The treatment received emergency approval from the US regulator in late December and has been cleared by the UK and EU.

Pfizer has made tens of billions of dollars during the pandemic from its Covid-related products, as has the Boston-based biotech firm Moderna, which was loss-making until it started selling a Covid-19 vaccine.

Tim Bierley, a pharma campaigner at Global Justice Now, said: “Throughout the pandemic, Pfizer has refused to share its technology and knowhow. Instead, it has maintained monopoly control over its vaccine and treatment, keeping a chokehold on global supply.

“Despite calls from campaigners to allow countries in the global south to manufacture their own vaccines and treatments, Pfizer continues to put profit over people’s health. Pfizer’s revenues almost doubled last year and now it looks like the company’s coffers are set to swell even further. At a time when millions still don’t have access to vaccines or treatments for Covid-19, this continued pandemic profiteering is harrowing.”

Pfizer’s revenues last year doubled to $81.3bn, and it expects to make record sales of $98bn to $102bn this year, half of which will come from Covid products – $32bn from Comirnaty and $22bn from Paxlovid.

On the issue of sharing intellectual property, Pfizer said others would struggle to produce its mRNA vaccine – one of only two on the market – arguing that “it is not as simple as sharing the ‘recipe’”. Manufacture of its vaccine involves more than 280 materials from 86 suppliers in 19 countries.

Other companies, led by AstraZeneca, Britain’s biggest drugmaker, and Johnson & Johnson, a big US firm, went down the not-for-profit route and priced their Covid vaccines at cost during the pandemic. Towards the end of last year, AstraZeneca moved away from its not-for-profit pricing in new contracts, but insists that it is still offering “equitable pricing”.

Pfizer said it also offered tiered pricing, with the wealthier nations paying in the range of about the cost of a takeaway meal, while the upper-middle-income countries were offered doses at roughly half that price and the low- and lower-middle-income countries were offered doses at a not-for-profit price.

In March, the company struck an agreement with Unicef to supply up to 4m treatment courses of Paxlovid to 95 low- and middle-income countries at a not-for-profit price.

Moderna has promised not to enforce its coronavirus vaccine patents in some low- and middle-income countries.
Newsletter

Related Articles

0:00
0:00
Close
Germany Enters Fiscal Crisis as Cabinet Approves €174 Billion in New Debt
Trump Administration Finalizes Broad Tariff Increases on Global Trade Partners
J.K. Rowling Limits Public Engagements Citing Safety Fears
JD.com Launches €2.2 Billion Bid for German Electronics Retailer Ceconomy
Azerbaijan Proceeds with Plan to Legalise Casinos on Artificial Islands
Former Judge Charged After Drunk Driving Crash Kills Comedian in Brazil
Jeff Bezos hasn’t paid a dollar in taxes for decades. He makes billions and pays $0 in taxes, LEGALLY
China Increases Use of Exit Bans Amid Rising U.S. Tensions
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
Procter & Gamble to Raise U.S. Prices to Offset One‑Billion‑Dollar Tariff Cost
House Republicans Move to Defund OECD Over Global Tax Dispute
Botswana Seeks Controlling Stake in De Beers as Anglo American Prepares Exit
Trump Administration Proposes Repeal of Obama‑Era Endangerment Finding, Dismantling Regulatory Basis for CO₂ Emissions Limits
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
A family has been arrested in the UK for displaying the British flag
Mel Gibson refuses to work with Robert De Niro, saying, "Keep that woke clown away from me."
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
The British propaganda channel BBC News lies again.
Deputy attorney general's second day of meeting with Ghislaine Maxwell has concluded
Controversial March in Switzerland Features Men Dressed in Nazi Uniforms
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
×